moves
Roche moves obesity drug into pivotal trials after mid-stage success
Andrew Joseph covers health, medicine and the biopharmaceutical industry in Europe. You can reach Andrew on Signal at drawqjoseph.71. Roche plans to launch Phase 3 studies of its lead obesity candidate this quarter after reporting Tuesday that the drug led to significant weight loss in a mid-stage trial. The drug, known as CT-388, caused an […]
1 min read